bioRxivNeurosciencePreprint
Non-microglial downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease-related hallmarks
Audrey CouloniD, Florian RabilleriD, Mari TakaloiD, Avishek RoyiD, Alexandre PelletieriD, Henna MartiskaineniD, Dolores Siedlecki‐WullichiD, Nina Lannette-WeimanniD, Naďa Majerníková, Arthur Grenon, Vance Difan GaoiD, Anaël Erhardt, Anne Pernodet, Morgane Lemaire, Floriane Limoge, Pauline WalleiD, Tiago MendesiD, Karine GuyotiD, Célia Lemeu, Lukas-Iohan Carvalho, Ana Raquel Melo de FariasiD, Marc HulsmaniD, Chloé Najdek, Alejandra Freire-Regatillo, Orthis SahaiD, , Jean‐Charles LambertiD
Abstract
We developed a high content screening to investigate how Alzheimer disease (AD) genetic risk factors may affect synaptic mechanisms in rat primary neuronal cultures. Out of the target genes identified, we found that Plcg2 downregulation in mouse dentate gyrus neurons consistently disrupted dendritic morphology and synaptic function. In human neuronal cultures (hNCs), PLCG2 downregulation also impaired synaptic function and increased A{beta} levels and Tau phosphorylation. Very rare PLCG2 loss-of-function (LoF) variants were associated with a 10-fold increased AD risk. PLCG2 LoF carriers exhibit low mRNA/protein PLCG2/PLC{gamma}2 levels and the R953* LoF mutation compromised synaptic function and increased AD hallmarks in hNCs. Single nuclei RNAseq analyses confirmed that the downregulation of PLCG2 impacted pathways related to synaptic and neuronal functions, potentially through neurexin in neurons. In conclusion, PLC{gamma}2 downregulation could increase AD risk by impairing synaptic functions and increasing the A{beta} levels and Tau phosphorylation in neurons.
- organism: rat
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Uncoupling of synaptic loss from amyloid burden by an Alzheimer's disease protective variant of PLCγ2.
Ryan J. Bevan, Emily Maguire, … Philip R. Taylor·bioRxiv·Sep 22, 2023
- PLCG2 as a Risk Factor for Alzheimer's Disease
Andy Po‐Yi Tsai, Chuanpeng Dong, … Kwangsik T. Nho·bioRxiv·May 19, 2020
- Protective variant in PLCgamma2 mitigates Alzheimer's disease associated pathology via enhancing beneficial microglia functions
Mari Takalo, Heli Jeskanen, … Mikko Hiltunen·bioRxiv·Sep 12, 2024
- Evidence for cPLA2 activation in Alzheimer's Disease Synaptic Pathology
Qiu-Lan Ma, Brandon Ebright, … Hussein N. Yassine·Acta Neuropathologica CommunicationsPeer-reviewed·Feb 12, 2026
- The Alzheimer's disease protective P522R variant of PLCG2, consistently enhances stimulus-dependent PLCγ2 activation, depleting substrate and altering cell function.
Emily Maguire, Georgina Elizabeth Menzies, … Philip R. Taylor·bioRxiv·Apr 27, 2020
- Genetic Variants of Phospholipase C-γ 2 Confer Altered Microglial Phenotypes and Differential Risk for Alzheimers Disease
Andy Po‐Yi Tsai, Chuanpeng Dong, … Gary E. Landreth·ImmunityPeer-reviewed·Sep 1, 2023